Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects.

Hasunuma T, Fukase H, Miyazaki A, Nishikawa Y.

Clin Drug Investig. 2017 Jul;37(7):679-685. doi: 10.1007/s40261-017-0525-0.

2.

Management standards for stable coronary artery disease in India.

Mishra S, Ray S, Dalal JJ, Sawhney JP, Ramakrishnan S, Nair T, Iyengar SS, Bahl VK.

Indian Heart J. 2016 Dec;68 Suppl 3:S31-S49. doi: 10.1016/j.ihj.2016.11.320. Epub 2016 Dec 9. Review.

3.
4.

A Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI].

Johnson TW, Mumford AD, Scott LJ, Mundell S, Butler M, Strange JW, Rogers CA, Reeves BC, Baumbach A.

PLoS One. 2015 Dec 16;10(12):e0144984. doi: 10.1371/journal.pone.0144984. eCollection 2015.

5.

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.

Norgard NB, DiNicolantonio JJ.

Ther Adv Chronic Dis. 2015 Jul;6(4):204-18. doi: 10.1177/2040622315584113. Review.

6.

Role of sodium tungstate as a potential antiplatelet agent.

Fernández-Ruiz R, Pino M, Hurtado B, García de Frutos P, Caballo C, Escolar G, Gomis R, Diaz-Ricart M.

Drug Des Devel Ther. 2015 May 26;9:2777-86. doi: 10.2147/DDDT.S77221. eCollection 2015.

7.

Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies.

Lombardi F, Golla K, Fitzpatrick DJ, Casey FP, Moran N, Shields DC.

PLoS Comput Biol. 2015 Apr 15;11(4):e1004119. doi: 10.1371/journal.pcbi.1004119. eCollection 2015 Apr.

8.

Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention.

Ozcan OU, Tutar E, Candemir B, Ustun EE, Erol C.

Int J Angiol. 2015 Mar;24(1):19-24. doi: 10.1055/s-0034-1395981.

9.

Cardiac purinergic signalling in health and disease.

Burnstock G, Pelleg A.

Purinergic Signal. 2015 Mar;11(1):1-46. doi: 10.1007/s11302-014-9436-1. Epub 2014 Dec 20. Review.

10.

Clopidogrel resistance: the way forward.

Ray S.

Indian Heart J. 2014 Sep-Oct;66(5):530-4. doi: 10.1016/j.ihj.2014.08.012. Epub 2014 Oct 7. Review.

11.

Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments.

Thind GS, Parida R, Gupta N.

Ther Clin Risk Manag. 2014 Oct 21;10:885-900. doi: 10.2147/TCRM.S71927. eCollection 2014. Review.

12.

Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).

Vrijens B, Claeys MJ, Legrand V, Vandendriessche E, Van de Werf F.

Br J Clin Pharmacol. 2014 May;77(5):746-55.

13.

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.

Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK.

Eur Heart J. 2014 Aug 14;35(31):2083-93. doi: 10.1093/eurheartj/ehu160. Epub 2014 Apr 11.

14.

Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention.

Jin HY, Yang TH, Choi KN, Seo JS, Jang JS, Kim DK, Kim DS.

Korean Circ J. 2014 Mar;44(2):82-8. doi: 10.4070/kcj.2014.44.2.82. Epub 2014 Mar 12.

15.

Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.

P V K, Kumar C U, J C S, P U, E C.

J Clin Diagn Res. 2013 Nov;7(11):2478-82. doi: 10.7860/JCDR/2013/6884.3584. Epub 2013 Oct 21.

16.

High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.

Garabedian T, Alam S.

Cardiovasc Diagn Ther. 2013 Mar;3(1):23-37. doi: 10.3978/j.issn.2223-3652.2013.02.06. Review.

17.

New antiplatelet agents for cardiovascular disease.

Chua D, Nishi C.

CMAJ. 2013 Nov 5;185(16):1405-11. doi: 10.1503/cmaj.130033. Epub 2013 Sep 9. Review. No abstract available.

18.

Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders.

Lee SH, Kim BK, Oh J, Park JS, Lee DJ, Lee HC, Kim JH, Hong MK.

Korean Circ J. 2013 May;43(5):343-6. doi: 10.4070/kcj.2013.43.5.343. Epub 2013 May 31.

20.

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.

Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, Ataga KI, Knupp CL, McMahon LE, Strouse JJ, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Riesmeyer JS, Winters KJ.

J Hematol Oncol. 2013 Feb 17;6:17. doi: 10.1186/1756-8722-6-17.

Supplemental Content

Support Center